Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;25(2):e25866.
doi: 10.1002/jia2.25866.

Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa

Dvora Leah Joseph Davey  1   2   3 , Rufaro Mvududu  2 , Nyiko Mashele  2 , Maia Lesosky  2 , Nehaa Khadka  1 , Linda-Gail Bekker  3 , Pamina Gorbach  1 , Thomas J Coates  4 , Landon Myer  2
Affiliations

Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa

Dvora Leah Joseph Davey et al. J Int AIDS Soc. 2022 Feb.

Abstract

Introduction: Pre-exposure prophylaxis (PrEP) is a safe and effective prevention strategy to reduce women's risk of HIV in pregnancy and postpartum. Effective PrEP protection requires daily PrEP adherence, but little is known about maternal PrEP continuation and factors that influence PrEP use.

Methods: The PrEP in pregnancy and postpartum (PrEP-PP) study enrolled consenting pregnant, HIV-negative women at first antenatal care (ANC) visit with follow-up through 12 months postpartum. Eligible and consenting women and girls ≥16 years received HIV prevention counselling and were offered PrEP. Interviewers collected socio-demographic and behavioural data from participants at each visit. We analysed the proportion of women who initiated PrEP and the proportion who continued PrEP after 3 months with associated correlates by estimating the prevalence ratio adjusting for a priori confounders.

Results: Between August 2019 and October 2021, we enrolled 1201 pregnant women (median gestation 21 weeks; age 26 years); 84% of women initiated PrEP at their first ANC visit (n = 1014); 55% were married or cohabiting. Overall, 66% of women on PrEP returned for a repeat prescription at 1 month; 58% returned at 3 months (n = 493 of 844). Almost one-half of women on PrEP reported a side effect at 1 month, mostly nausea/vomiting. Women on PrEP in the first and second trimesters had higher odds of reporting side effects (aOR 2.61; 95% CI 1.17-5.84) versus postpartum women. Women who reported side effects continued with PrEP less than those who did not report side effects (aPR = 0.87; 95% CI 0.77-0.97). Women with ≥1 previous pregnancy (aPR = 0.76; 95% CI 0.57-1.01) or were postpartum (aPR 0.85; 95% CI 0.75-0.97) were less likely to continue PrEP compared to women who were primigravid or pregnant. Women who reported having an HIV+ partner (aPR = 1.45; 95% CI 1.13-1.85) or high HIV risk perception (aPR = 1.20, 95% CI = 1.01-1.41) were more likely to continue on PrEP than those who had HIV-negative partners or low risk perception.

Conclusions: PrEP initiation and early continuation were high in this setting, compared to other studies in women. Being postpartum and experiencing side effects were associated with lower PrEP continuation, presenting opportunities for counselling on early transient side effects. Interventions for postpartum women on PrEP are needed.

Trial registration: ClinicalTrials.gov NCT03826199.

Keywords: South Africa; adherence; breastfeeding; cohort studies; pre-exposure prophylaxis; pregnant.

PubMed Disclaimer

Conflict of interest statement

We received the study drug (Truvada®) from Gilead Sciences (Foster City, CA, USA) and STI test kits from Cepheid Inc. (Sunnyvale, CA, USA).

Figures

Figure 1
Figure 1
Side effects reported by pregnant women on PrEP and how much it bothered them.
Figure 2
Figure 2
Reasons for missing PrEP doses among pregnant and postpartum women at 3 month follow‐up (n=387 women who missed 1+ PrEP doses).
See this image and copyright information in PMC

References

    1. Drake AL, Wagner A, Richardson B, John‐Stewart G. Incident HIV during pregnancy and postpartum and risk of mother‐to‐child HIV transmission: a systematic review and meta‐analysis. PLoS Med. 2014;11(2):e1001608. - PMC - PubMed
    1. Thomson KA, Hughes J, Baeten JM, John‐Stewart G, Celum C, Cohen CR, et al. Increased risk of female HIV‐1 acquisition throughout pregnancy and postpartum: a prospective per‐coital act analysis among women with HIV‐1 infected partners. J Infect Dis. 2018;218:16–25. - PMC - PubMed
    1. Mofenson LM. Tenofovir pre‐exposure prophylaxis for pregnant and breastfeeding women at risk of HIV infection: the time is now. PLoS Med. 2016;13(9):e1002133. - PMC - PubMed
    1. Pintye J, Davey DLJ, Wagner AD, John‐Stewart G, Baggaley R, Bekker LG, et al. Defining gaps in pre‐exposure prophylaxis delivery for pregnant and post‐partum women in high‐burden settings using an implementation science framework. Lancet HIV. 2020;7(8):e582–92. - PMC - PubMed
    1. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother‐to‐child transmission of HIV. J Acquir Immune Defic Syndr. 2012;59(4):417–25. - PMC - PubMed

Publication types

Substances

Associated data